Evgeniia N Bykonia, Denis A Kleymenov, Vladimir A Gushchin, Andrei E Siniavin, Elena P Mazunina, Sofia R Kozlova, Anastasia N Zolotar, Evgeny V Usachev, Nadezhda A Kuznetsova, Elena V Shidlovskaya, Andrei A Pochtovyi, Daria D Kustova, Igor A Ivanov, Sergey E Dmitriev, Roman A Ivanov, Denis Y Logunov, Alexander L Gintsburg
SARS-CoV-2 variants have evolved over time in recent years, demonstrating immune evasion of vaccine-induced neutralizing antibodies directed against the original S protein. Updated S-targeted vaccines provide a high level of protection against circulating variants of SARS-CoV-2, but this protection declines over time due to ongoing virus evolution. To achieve a broader protection, novel vaccine candidates involving additional antigens with low mutation rates are currently needed. Based on our recently studied mRNA lipid nanoparticle (mRNA-LNP) platform, we have generated mRNA-LNP encoding SARS-CoV-2 structural proteins M, N, S from different virus variants and studied their immunogenicity separately or in combination in vivo...
April 2, 2024: Vaccines